Department of Neurology, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, China.
The Second School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, China.
J Neurochem. 2022 Sep;162(5):390-403. doi: 10.1111/jnc.15685. Epub 2022 Aug 16.
Sphingosine-1-phosphate (S1P) is a bioactive lysophospholipid that can influence a broad range of biological processes through its binding to five distinct G-protein-coupled receptors. S1P receptor modulators are a new group of immunosuppressive agents currently used in the immunotherapy of multiple sclerosis. Inflammation following stroke can exacerbate neuronal injury. Given that S1P signaling is linked to multiple immune processes, therapies targeting the S1P axis may be suitable for treating stroke. In this review, we outline S1P metabolism and S1P receptors, discuss the mechanisms of action of S1P receptor modulators in lymphocyte migration and their direct action on cells of the central nervous system, and provide a concise summary of the efficacy of S1P receptor modulators in animal studies and clinical trials on treatments for stroke.
鞘氨醇-1-磷酸（S1P）是一种生物活性溶血磷脂，可通过与五个不同的 G 蛋白偶联受体结合来影响广泛的生物学过程。S1P 受体调节剂是一组新型免疫抑制剂，目前用于多发性硬化症的免疫治疗。中风后的炎症可加重神经元损伤。鉴于 S1P 信号与多种免疫过程有关，靶向 S1P 轴的治疗方法可能适用于治疗中风。在这篇综述中，我们概述了 S1P 代谢和 S1P 受体，讨论了 S1P 受体调节剂在淋巴细胞迁移中的作用机制及其对中枢神经系统细胞的直接作用，并简要总结了 S1P 受体调节剂在动物研究和临床试验中的疗效中风的治疗。
